OUR PARTNERS

Working with others

OUR PARTNERS

We are actively building meaningful partnerships with other research funding organisations, patient-led charities, and biotechnology and pharmaceutical companies working to the benefit of people affected by prostate cancer. In doing so, we aim to ensure that the development of new treatments for prostate cancer is: addressing areas of critical unmet need; informed by shared knowledge and expertise; and placing the patient voice at the heart of everything we do.

In 2021, Prostate Cancer Research is delighted to be partnering with The Mark Foundation for Cancer Research to co-sponsor an exciting new project led by Dr Jennifer Munkley at the Centre for Cancer, Newcastle University. Over 24 months, Dr Munkley aims to investigate three ‘glycan sugars’ that she has previously discovered to be at very high levels in individuals whose cancer has spread to bone and are important to tumour growth, with the aim of determining whether targeting these sugars could be the basis of a new cancer treatment. As there are pre-existing drugs used to treat other diseases that can stop glycan sugars working, Dr Munkley intends to find out if these drugs can also be used to stop prostate cancer spreading.

The pandemic has had a devastating effect on medical research, with the Association of Medical Research Charities calculating that roughly £270 million in research funding has been cut since the pandemic started. However, at PCR, we proceeded with our plans to fund new research, and we are really pleased to be partnering with the US-based Mark Foundation that has also worked to close that gap. In addition to the $250,000 they have put towards funding Dr Munkley’s research, they have now committed nearly $24 million towards other cancer foundations to help support research projects that would have lost funding.

IN PARTNERSHIP WITH